Pharmacological therapy for acute respiratory distress syndrome

Mayo Clinic Proceedings

Volumn 81, Issue 2, 2006, Pages 205-212

  Jain, Raksha ^a   DalNogare, Anthony ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ACETYLCYSTEINE; ANTIOXIDANT; CORTICOSTEROID; CYTOKINE ANTIBODY; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; FISH OIL; GROWTH FACTOR; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 8 ANTIBODY; KETOCONAZOLE; LISOFYLLINE; LUNG SURFACTANT; METHYLPREDNISOLONE; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN E1; SODIUM CHANNEL; TEZOSENTAN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG MECHANISM; FIBRIN DEPOSITION; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG FLUID; LUNG INJURY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SHEEP; VENTILATOR;

EID: 32144459541     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.2.205     Document Type: Review

References (73)

1. Weinacker AB, Vaszar LT. Acute respiratory distress syndrome: physiology and new management strategies. Annu Rev Med. 2001;52:221-237.
2. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3, pt 1):818-824.
3. Hudson LD, Steinberg KP. Epidemiology of acute lung injury and ARDS. Chest. 1999;116(1, suppl):74S-82S.
4. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301-1308.
5. Bower RG, Lanken PN, MacIntyre N, et al, National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004;351:327-336.
6. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334-1349.
7. Herridge MS, Cheung AM, Tansey CM, et al, Canadian Critical Care Trials Group. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003;348:683-693.
8. Bellingan GJ. The pulmonary physician in critical care: the pathogenesis of ALI/ARDS. Thorax. 2002;57:540-546.
9. Siegel MD. Novel therapies for the acute respiratory distress syndrome. Updated May 24, 2005. Available at: www.uptodate.com/. Accessed July 12, 2005.
10. Weigelt JA, Norcross JF, Borrnan KR, Snyder WH III. Early steroid therapy for respiratory failure. Arch Surg. 1985;120:536-540.
11. Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with acute respiratory distress syndrome. N Engl J Med. 1987;317:1565-1570.
12. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methyl-prednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280:159-165.
13. Brun-Buisson C, Brochard L. Corticosteroid therapy in acute respiratory distress syndrome: better late than never? [editorial]. JAMA. 1998;280:182-183.
14. Mikawa K, Akamatsu H, Maekawa N, Nishina K, Obara H, Niwa Y. Inhibitory effect of prostaglandin E1 on human neutrophil function. Prostaglandins Leukot Essent Fatty Acids. 1994;51:287-291.
15. Holcroft JW, Vassar MJ, Weber CJ. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome: a prospective trial. Ann Surg. 1986;203:371-378.
16. Bone RC, Slotman G, Maunder R, et al, Prostaglandin E1 Study Group. Randomized double-blind, multicenter study of prostaglandin E1 in patients with acute respiratory distress syndrome. Chest. 1989;96:114-119.
17. Abraham E, Park YC, Covington P, Conrad SA, Schwanz M. Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind multicenter clinical trial. Crit Care Med. 1996;24:10-15.
18. Abraham E, Baughman R, Fletcher E, et al, TLC C-53 ARDS Study Group. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. Crit Care Med. 1999;27:1478-1485.
19. Ullrich R, Bloch KD, Ichinose F, Steudel W, Zapol WM. Hypoxic pulmonary blood flow redistribution and arterial oxygenation in endotoxin-challenged NOS2-deficient mice. J Clin Invest. 1999;104:1421-1429.
20. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328:399-405.
21. Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C, European Study Group of Inhaled Nitric Oxide. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. Intensive Care Med. 1999;25:911-919.
22. Michael JR, Barton RG, Saffle JR, et al. Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med. 1998;157(5, pt 1):1372-1380.
23. Troncy E, Collet JP, Shapiro S, et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med. 1998;157(5, pt 1):1483-1488.
24. Gerlach H, Keh D, Semmerow A, et al. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am J Respir Crit Care Med. 2003;167:1008-1015.
25. Dellinger RP, Zimmerman JL, Taylor RW, et al, Inhaled Nitric Oxide in ARDS Study Group. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Crit Care Med. 1998;26:15-23.
26. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med. 2003;349:2099-2107.
27. Van Meurs KP, Wright LL, Ehrenkranz RA, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005;353:13-22.
28. Martin RJ, Walsh MC. Inhaled nitric oxide for preterm infants - who benefits? [editorial]. N Engl J Med. 2005;353:82-84.
29. Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154(6,pt 1):1671-1677.
30. Spragg RG, Lewis JF, Wurst W, et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med. 2003;167:1562-1566.
31. Anzueto A, Baughman RP, Guntupalli KK, et al, Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. Aerosolized surfactant in adults with sepsis-induced respiratory distress syndrome. N Engl J Med. 1996;334:1417-1421.
32. Gregory TJ, Steinberg KP, Spragg R, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1997;155:1309-1315.
33. Lewis JF, Veldhuizen R. The role of exogenous surfactant in the treatment of acute lung injury. Annu Rev Physiol. 2003;65:613-642.
34. Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med. 2004;351:884-892.
35. Willson DF, Thomas NJ, Markovitz BP, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial [published correction appears in JAMA. 2005;294:900], JAMA. 2005;293:470-476.
36. Brower RG, Ware LB, Berthiaume Y, Matthay MA. Treatment of ARDS. Chest. 2001;120:1347-1367.
37. ARDS Clinical Trials Network, National Heart, Lung, and Blood Institute, National Institutes of Health. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med. 2002;30:1-6.
38. Slotman GJ, Burchard KW, D'Arezzo A, Gann DS. Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J Trauma. 1988;28:648-654.
39. Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med. 1993;21:1635-1642.
40. Sinuff T, Cook DJ, Peterson JC, Fuller HD. Development, implementation, and evaluation of ketoconazole practice guidelines for ARDS prophylaxis. J Crit Care. 1999;14:1-6.
41. ARDS Network. Ketoconazole for the early treatment of acute lung injury and acute respiratory distress syndrome [published corrections appear in JAMA. 2000;284:2450; JAMA. 2000;284:2597; and JAMA. 2001;286:1578], JAMA. 2000;283:1995-2002.
42. Wagner PD, Mathieu-Costello O, Bebout DE, Gray AT, Natterson PD, Glennow C. Protection against pulmonary O2 toxicity by N-acetylcysteine. Eur Respir J. 1989;2:116-126.
43. Jepsen S, Herlevsen P, Knudsen P, Bud MI, Klausen NO. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit Care Med. 1992;20: 918-923.
44. Bernard GR, Wheeler AP, Arons MM, et al, Antioxidant in ARDS Study Group. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest. 1997;112:164-172.
45. Suter PM, Domenighetti G, Schaller MD, Laverriere MC, Ritz R, Perret C. N-acetylcysteine enhances recovery from acute lung injury in man: a randomized, double-blind, placebo-controlled clinical study. Chest. 1994;105:190-194.
46. Gadek JE, DeMichele SJ, Karlstad MD, et al, Enteral Nutrition in ARDS Study Group. Effect of enteral feeding with eicosapentaenoic acid, gammalinolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Crit Care Med. 1999;27:1409-1420.
47. Beale RJ, Bryg DJ, Bihari DJ. Immunonutrition in the critically ill: a systematic review of clinical outcome. Crit Care Med. 1999;27:2799-2805.
48. Cranshaw J, Griffiths MJD, Evans TW. The pulmonary physician in critical care, part 9: non-ventilatory strategies in ARDS. Thorax. 2002;57:823-829.
49. Moss M, Bucher B, Moore FA, Moore EE, Parsons PE. The role of chronic alcohol abuse in the development of acute respiratory distress syndrome in adults. JAMA. 1996;275:50-54.
50. Matthay MA, Zimmerman GA, Esmon C, et al. Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med. 2003;167:1027-1035.
51. Matthay MA, Folkesson HG, Verkman AS. Salt and water transport across alveolar and distal airway epithelia in the adult lung. Am J Physiol. 1996;270(4, pt 1):L487-L503.
52. Berthiaume Y, Folkesson HG, Matthay MA. Lung edema clearance: 20 years of progress: invited review: alveolar edema fluid clearance in the injured lung. J Appl Physiol. 2002;93:2207-2213.
53. Sakuma T, Folkesson HG, Suzuki S, Okaniwa G, Fujimura S, Matthay MA. Beta-adrenergic agonist stimulated alveolar fluid clearance in ex vivo human and rat lungs. Am J Respir Crit Care Med. 1997;155:506-512.
54. Lasnier JM, Wangensteen OD, Schmitz LS, Gross CR, Ingbar DH. Terbutaline stimulates alveolar fluid resorption in hyperoxic lung injury. J Appl Physiol. 1996;81:1723-1729.
55. Saldias FJ, Comellas A, Ridge KM, Lecuona E, Sznajder JI. Isoproterenol improves ability of lung to clear edema in rats exposed to hyperoxia. J Appl Physiol. 1999;87:30-35.
56. Tibayan FA, Chesnutt AN, Folkesson HG, Eandi J, Matthay MA. Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. Am J Respir Crit Care Med. 1997;156(2,pt 1):438-444.
57. Barnard ML, Olivera WG, Rutschman DM, Bertorello AM, Katz AI, Sznajder JI. Dopamine stimulates sodium transport and liquid clearance in rat lung epithelium. Am J Respir Crit Care Med. 1997;156(3, pt 1):709-714.
58. Lai KN, Leung JC, Metz CN, Lai FM, Bucala R, Lan HY. Role for macrophage migration inhibitory factor in acute respiratory distress syndrome. J Pathol. 2003;199:496-508.
59. Yano T, Deterding RR, Simonet WS, Shannon JM, Mason RJ. Keratinocyte growth factor reduces lung damage due to acid instillation in rats. Am J Respir Cell Mol Biol. 1996;15:433-442.
60. Panos RJ, Bak PM, Simonet WS, Rubin JS, Smith LJ. Intratracheal instillation of keratinocyte growth factor decreases hyperoxia-induced mortality in rats. J Clin Invest. 1995;96:2026-2033.
61. Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol. 2000;22:401-404.
62. Idell S. Anticoagulants for acute respiratory distress syndrome: can they work? Am J Respir Crit Care Med. 2001;164:517-520.
63. Bernard GR, Vincent JL, Laterre PF, et al, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
64. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med. 2001;29:2081-2089.
65. Abraham E, Reinhart K, Opal S, et al, OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-247.
66. Blackwell TS, Blackwell TR, Holden EP, Christman BW, Christman JW. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol. 1996;157:1630-1637.
67. Mitaka C, Hirata Y, Nagura T, Tsunoda Y, Amaha K. Circulating endothelin-1 concentrations in acute respiratory failure. Chest. 1993;104:476-480.
68. Langleben D, DeMarchie M, Laporta D, Spanier AH, Schlesinger RD, Stewart DJ. Endothelin-1 in acute lung injury and the adult respiratory distress syndrome. Am Rev Respir Dis. 1993;148(6, pt 1):1646-1650.
69. Cox RA, Enkhabaatar P, Burke AS, et al. Effects of a dual endothelin-1 receptor antagonist on airway obstruction and acute lung injury in sheep following smoke inhalation and burn injury. Clin Sci (Lond). 2005;108:265-272.
70. Kuklin VN, Kirov MY, Evgenov OV, et al. Novel endothelin receptor antagonist attenuates endotoxin-induced lung injury in sheep. Crit Care Med. 2004;32:766-773.
71. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts poor outcome. Chest. 1995;108:1303-1314.
72. Folkesson HG, Matthay MA, Hebert CA, Broaddus VC. Acid aspiration-induced lung injury in rabbits is mediated by interleukin-8-dependent mechanisms. J Clin Invest. 1995;96:107-116.
73. Pittet JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med. 1997;155:1187-1205.